Filing Flows › Eton Pharmaceuticals (ETON) › R&D spending
Eton Pharmaceuticals (ETON) R&D spending by quarter
Eton Pharmaceuticals' R&D spending was $5.3M in Q3 2026 (third quarter 2026), +431% from Q2 2026. Over the last 7 quarters it ranged from $993K (Q2 2026) to $5.3M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $5.3M | +431% | +374% |
| Q2 2026 | $993K | -47% | -73% |
| Q1 2026 | $1.9M | +5% | +61% |
| Q4 2025 | $1.8M | +60% | — |
| Q3 2025 | $1.1M | -70% | — |
| Q2 2025 | $3.7M | +220% | — |
| Q1 2025 | $1.2M | — | — |
Q3 2026 at a glance
Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%, net earnings $35.2M, operating cash flow $35.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Eton Pharmaceuticals' R&D spending?
Eton Pharmaceuticals' R&D spending was $5.3M in Q3 2026 (third quarter 2026), +431% from Q2 2026.
How has Eton Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $993K (Q2 2026) to $5.3M (Q3 2026).